149 results about "Intra ocular pressure" patented technology

Systems and methods for delivering multiple ocular implants to reduce intraocular pressure are disclosed. The ocular implants can be implanted at multiple sites within a single human eye without requiring removal of the delivery apparatus from the eye. A system for delivering multiple ocular implants can include at least two implants preloaded within a delivery device and configured to be implanted within the eye, a metering device configured to transfer energy to the implants for delivery at selected locations within the eye, wherein the metering device is configured to meter a variable amount of energy for each implant delivery event in the eye. The system can further include an injector mechanism configured to serially engage and drive each of the implants.

Systems and methods for delivering multiple ocular implants to reduce intraocular pressure are disclosed. The ocular implants can be implanted at multiple sites within a single human eye without requiring removal of the delivery apparatus from the eye. A system for delivering multiple ocular implants can include a plurality of implants, an external housing, and an introducer assembly. The external housing can provide access to an implant singulation actuator and an implant delivery actuator. The introducer assembly can comprise an auto-retracting introducer portion. The delivery apparatus can include an infinite activation mechanism / portion and / or a manual singulation mechanism / portion.

Surgical treatment of glaucoma involves creation of a sclerocorneal drainage channel, ensuring long-lasting controlled fluid flow and reduced intraocular pressure. Limitations relate to collateral damage to adjacent structures and outcomes being heavily reliant on the surgeon's expertise. The device described herein addresses such shortcomings. The device comprises a grasping body having a longitudinal axis, and a piercing member coupled to the grasping body, including an elongate body and a beveled piercing tip including a long side and a short side, wherein the piercing member includes a proximal segment, a distal segment, and an aperture nested between the proximal segment and the distal segment, wherein the short side and the aperture are coaxially disposed along a central longitudinal axis of the piercing member, and wherein the piercing member is configured to reciprocate along the longitudinal axis relative to the grasping body.

Disclosed herein are systems, devices, kits, and associated methods for treating conditions of the eye by reducing intraocular pressure. The system may include an ocular implant and a delivery device. The ocular implant may be implantable within Schlemm's canal to restore or maintain at least partial patency of the canal without substantially interfering with transmural or transluminal fluid flow across the canal. The delivery device may include a cannula comprising a straight proximal portion and a curved distal portion, where the curved distal portion comprises a first curve in a first direction. The delivery device may also include a positioning tool positioned at least partially within the cannula and configured to advance the ocular implant through the cannula, where the positioning tool comprises a curved distal portion biased to form a second curve in a second, different direction.

An implant and method for regulating the intraocular pressure of an eye is described. The implant is disposed in Schlemm's canal of an eye through ab-externo or ab-interno canaloplasty. Once inserted, the implant monitors the intraocular pressure of an eye with a pressure sensor and provides regulated current to electrodes within the implant to perform electrolysis. Electrolysis causes a release of gas from the eye and a reduction in the volume of aqueous humor to decrease intraocular pressure. The degree of electrolysis and reduction of intraocular pressure is regulated by a platform that includes monitoring by a pressure sensor, safety controls, and remote access.

A wireless passive resonance sensor and contact lens for intraocular pressure monitoring comprises a contact lens body which is used for packaging a sensor assembly and serves as a substrate of the sensor. The first spiral inductor is arranged in the contact lens body; the middle elastic dielectric layer covers the first spiral inductor and is used for forming a deformable dielectric medium; the second spiral inductor is arranged on the middle-layer elastic dielectric layer, is opposite to the first spiral inductor and forms an inductor assembly with the first spiral inductor; wherein the first spiral inductor, the middle elastic dielectric layer and the second spiral inductor jointly form a capacitor and equivalently form a serial L-C-L resonant circuit, and the change of intraocular pressure is responded through the change of resonant frequency of the resonant circuit, so that passive wireless monitoring is realized. The design optimizes the preparation process, reduces the cost, improves the signal stability, is suitable for 24-hour continuous monitoring, and provides a powerful tool for early diagnosis and intervention of glaucoma.

The invention provides an eye drop composition as well as a preparation method and application thereof, and belongs to the technical field of ophthalmic preparations. The eye drop composition adopted by the invention is prepared from the following components: brimonidine tartrate, hyaluronic acid, collagen, trehalose and injection water. By compounding the components, the eye drops which can realize slow release of brimonidine tartrate and prolong the antihypertensive action time and have the characteristics of relieving blink discomfort, long-acting moisturizing, anti-inflammatory soothing, mildness, corrosion prevention and the like are prepared; the eye drops are beneficial to people suffering from glaucoma, intraocular hypertension, xerophthalmia, postoperative inflammation or allergy and preservative sensitivity or preservative allergy, the life quality is improved, and diseases are relieved.

The invention relates to a computer-implemented method for calculating an intraocular lens (IOL). The method comprises calculating the IOL based on a biometric parameter of an eye to be treated with the IOL. Calculating the IOL involves taking into account the following: an expected change to the intraocular pressure as a result of treating the eye to be treated with the IOL compared to an intraocular pressure of the eye to be treated prior to treating the eye to be treated with the IOL; an expected intraocular pressure after treating the eye to be treated with the IOL; and / or an intraocular pressure prior to treating the eye to be treated with the IOL.

The invention belongs to the technical field of medicines, and discloses an application of a Necrosulfenamide (NSA) compound in preparation of a medicine for resisting glaucoma trabecular network fibrosis. The NSA can inhibit abnormal activation of necroptosis-related pathways and significantly down-regulate fibrosis key factors, so that the structure and function of trabecular meshwork tissues are improved, and the aqueous humor outflow capacity is recovered. It is found for the first time that NSA not only has a stable and lasting intraocular pressure lowering effect, but also can reduce retinal ganglion cell damage in an intraocular hypertension state, and has definite treatment and protection effects on non-acute glaucoma and intraocular hypertension. The regulation effect of NSA on trabecular meshwork fibrosis is not disclosed in the prior art, the research blank in the field is filled, and a new pharmacological target and a clinical application strategy are provided for prevention and treatment of glaucoma and related intraocular hypertension diseases.

The invention belongs to the technical field of micro electro mechanical systems, and particularly relates to a non-contact type intraocular pressure visual calibration method, which comprises the following steps of: by virtue of a human eye simplified AI model and an intraocular pressure deformation quantity detection device, combining an MEMS (Micro Electro Mechanical System) technology and a visual analysis theory, carrying out real-time and dynamic simulation on the human eye pressure, and carrying out data acquisition by an optical or image sensor; therefore, accurate monitoring of cornea deformation is realized, a more accurate intraocular pressure evaluation means is provided, and effective verification of the non-contact tonometer is realized. Compared with the prior art, the system has the beneficial effects that data acquisition is carried out by means of an optical sensor or an image sensor and the like, accurate monitoring of cornea deformation can be realized, an integration technology is adopted, cornea deformation quantity calculation and an analysis algorithm are integrated in the MEMS sensor, accurate monitoring of human cornea pressure can be realized, and the system is suitable for popularization and application. And dynamic monitoring can be realized.

The present disclosure relates to the treatment and / or prevention of glaucoma and other diseases affecting the optic nerve and retinal ganglion cells. In particular, the present disclosure provides novel therapeutic antibodies, and related compositions and methods, that target angiopoietin-related protein 7 (ANGPTL7) to reduce intraocular pressure (IOP) in order to prevent optic nerve damage and restore vision.

A glaucoma treatment apparatus including an imaging device capable of imaging the anterior segment of the eye, a treatment laser, an algorithm programmed to determine a location and a cross sectional area of a treatment based on a customized anatomy of the anterior segment of the eye including the trabecular meshwork (TM), the Schlemm's Canal (SC) and collector channels (CCS), obtained from pre-operative images of the anterior segment of the eye, a pre-operative intraocular pressure (IOP) level and a target IOP reduction as an inputs, and a processor configured to actuate the apparatus to create an outflow channel with a cross-sectional area and location or multiple outflow channels with multiple cross-sectional areas and locations from the anterior chamber (AC) to the SC across the TM, as determined by the algorithm to achieve the target intraocular pressure (IOP) reduction. Also disclosed is a method of reducing intraocular pressure in an eye.

Surgical treatment of glaucoma involves creation of a sclerocorneal drainage channel, ensuring long-lasting controlled fluid flow and reduced intraocular pressure. Limitations relate to collateral damage to adjacent structures and outcomes being heavily reliant on the surgeon's expertise. The device described herein addresses such shortcomings. The device comprises a body for grasping, a piercing member including a proximal segment and a distal segment, the distal segment including a piercing tip at a distal end thereof, and a distal stabilizer element extending from a distal end of the body, the distal stabilizer element including a lumen, wherein the piercing member is configured to reciprocate from a stored position, wherein the proximal segment is retracted within the stabilizer lumen and the piercing tip extends outwardly from the stabilizer, and an extended position, wherein the distal segment and at least a portion of the proximal segment extend outwardly from the stabilizer.

An intraocular pressure (IOP) maintenance device for maintaining IOP is disclosed. The IOP maintenance device includes an inlet configured to receive fluids from a first portion of the eye, an outlet configured to drain the fluids into a second portion of the eye, and a pressure regulator disposed between the inlet and the outlet, the pressure regulator comprising a pressure resistance apparatus configured to fluidly couple the inlet and the outlet when a pressure force from the first portion of the eye exceeds a threshold value, wherein fluid coupling of the inlet and the outlet enables drainage of the fluids from the first portion of the eye to the second portion of the eye to maintain the IOP.

The present invention relates to the technical field of pharmaceuticals, and in particular to a class of nitric oxide (NO) donor-containing compounds or pharmaceutically acceptable salts, a preparation method therefor, a pharmaceutical composition, and a use thereof in the treatment or prevention of an ocular hypertension-related ophthalmic disease and an optic nerve injury-related disease.

The invention discloses an implanted micropump driving system and method for glaucoma treatment, and relates to the field of driving systems.The driving system comprises a receiving coil, a power management module, a microprocessor control module and a driving module, the receiving coil is connected with the power management module, and the microprocessor control module is connected with the driving module; the power supply management module is respectively connected with the microprocessor control module and the driving module, and the microprocessor control module is connected with the driving module; the driving method comprises the following steps that the receiving coil receives energy of the transmitting coil, the power management module converts the energy into a stable power supply voltage signal and transmits the power supply voltage signal to the microprocessor control module and the driving module, and the microprocessor control module generates an analog signal and a control signal; the driving module processes the analog signal and the control signal, outputs a high-voltage square wave signal, and drives the piezoelectric micropump through the high-voltage square wave signal; secondary injury to the patient is reduced, the micropump is accurately controlled, and the intraocular pressure of the glaucoma patient is effectively reduced.

The invention relates to the technical field of medical apparatus and instruments, in particular to an intraoperative viscoelastic agent suction instrument for intraocular lens implantation, which comprises a replacement host, a liquid supply pump, a suction pump and a controller electrically connected with the liquid supply pump and the suction pump, the replacement main machine is further provided with a liquid inlet and a liquid outlet which are communicated with the liquid supply pump, and a suction port and a liquid discharge port which are communicated with the suction pump. An input connector and an output connector are arranged at one end of the handle, a replacement pipe is arranged at the other end of the handle, a liquid adding hole and a suction hole are formed in the free end of the replacement pipe, the liquid adding hole is communicated with the input connector, and the suction hole is communicated with the output connector. By balancing perfusion and suction amounts, intraoperative intraocular pressure fluctuation is avoided, intraoperative intraocular pressure caused by high intraocular pressure or intraocular pressure caused by excessive suction is avoided, and therefore the risk of optic nerve or retina injury is reduced.

The present invention relates to the application of an EphA2-specific tyrosine kinase inhibitor, ALW-II-41-27, in ophthalmic diseases. The present invention has confirmed that at a specific concentration, ALW-II-41-27 can inhibit the expression of EphA2 in the retina, reduce the damage of acute high intraocular pressure to retinal tissue, and improve the survival rate of retinal ganglion cells, thereby playing a neuroprotective role, and thus being used for the preparation of treatments for preventing and treating acute high intraocular pressure or glaucoma.

The present disclosure pertains to the field of animal disease models, specifically to a method for constructing an animal model of open-angle glaucoma. In this model, the pathogenesis of open-angle glaucoma is mimicked by inducing necroptosis in trabecular meshwork cells through the injection of IFN-γ into the anterior chamber. This process leads to the inhibition of trabecular meshwork activity and functional impairment, resulting in elevated intraocular pressure and subsequent optic nerve changes indicative of glaucoma. The pathophysiological alterations observed in the animal model closely resemble those seen in human open-angle glaucoma, including chamber angle opening, trabecular meshwork dysfunction, increased intraocular pressure, and loss of RGCs.

The present technology provides systems, devices, and methods for forming blebs to treat ocular hypertension or glaucoma. In some embodiments, a minimally invasive bleb formation device comprises an introducer sheath having a lumen extending longitudinally therethrough. The lumen has a distal end aperture insertable adjacent to a target tissue. The device further includes a wire positionable within the lumen of the introducer sheath. The wire has a first end portion, a second end portion, and an intermediate region between the first end portion and the second end portion. At least a segment of the intermediate portion is configured to extend through the distal end aperture to form a wire loop. The wire loop is moveable between a plurality of positions and is configured to disrupt and cauterize the target tissue.

The purpose of the present invention is to discover an eye drop capable of effectively lowering intraocular pressure even at night, especially during night sleep, in patients with glaucoma or ocular hypertension.　The present invention is an eye drop for lowering intraocular pressure during night sleep in patients suffering from glaucoma or ocular hypertension, the eye drop containing sepetaprost at a concentration of 0.002% (w / v) as an active ingredient.

A system for treating an eye comprising a tissue stored within a lumen of an elongated cannula, the tissue comprises scleral. amniotic membrane, or acellular biomatrix tissue and having an elongated form factor. Related devices, systems, and methods are provided.

This disclosure relates to a drug delivery system comprising an intraocular pressure lowering agent, a neurotrophic agent, such as a CNTF compound, a C-type Natriuretic Peptide (CNP) compound, a Tie-2 agonist, a Natriuretic Peptide Receptor-B (NPR-B) compound, or an apoptosis signaling fragment inhibitor (FAS) or FAS-ligand (FASL) inhibitor, including any combination of these compounds and a sustained delivery component. Methods of treating a glaucoma or related conditions, medicaments, kits, uses and methods of manufacturing are also described.

According to the pharmaceutical composition for treating glaucoma and intraocular hypertension provided by the invention, the stability of the pharmaceutical composition is obviously improved through a salt changing technology; the pharmaceutical composition is prepared from netasdil free alkali or a pharmaceutically acceptable salt thereof, timolol free alkali or a pharmaceutically acceptable salt thereof, and dorzolamide free alkali or a pharmaceutically acceptable salt thereof. The pharmaceutical composition has excellent stability when the pH value is 4.5-5.4. According to the present invention, the effective dose of the pharmaceutical composition is applied to the eyes of the patient requiring the intraocular pressure at the sleeping time or at the time close to the sleeping time once a day, such that the intraocular pressure can be efficiently and rapidly reduced so as to maintain the intraocular pressure in the physiological range for a long time, the side effect is small, and the patient compliance is high.

An ocular compression device with light directed through the sclera. The compression device may detachably house a lighting device that can be used to illuminate the eye area during ophthalmic surgery. Integrating the lighting device with the compression device during the procedure may reduce the number of hands required to perform the surgery. This may be particularly beneficial for ophthalmic surgery where the available surgical space is limited.

The invention discloses a dual-channel drug delivery treatment system for open-angle glaucoma night intraocular hypertension, and relates to the technical field of medical instruments and clinical assistance. The system comprises a central control module, a time window control module, an intelligent double-medicine-bin medicine feeding module, a user interaction module, a data management and analysis module, a communication module, a safety and self-checking module and a power supply and management module. According to the invention, through the time window control module, the traditional morning administration is changed into night administration or individualized administration before intraocular pressure peak, the synchronization of the drug action peak and the night intraocular pressure peak is ensured, and through the intelligent double-drug-bin administration module and the precise metering pump, two drugs with the lowest effective dose are precisely delivered strictly according to the specific sequence of PGA first and CAI second; the time sequence control and precise quantitative administration based on the drug synergistic effect mechanism can ensure the synergistic antihypertensive curative effect, and can obviously avoid the high incidence rate adverse reaction caused by standard dosage combination.

Provided herein are compounds comprising a formula of 4-(3- amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-y I) benzyl adamantane carboxylate (e.g., compounds of formula (I) ) or a pharmaceutically acceptable salt thereof. The compounds are useful for reducing intraocular pressure and for treating glaucoma or ocular hypertension. Formula (I).

The present application relates to a nitric oxide donor-type compound and use thereof in the preparation of a medicament for preventing and / or treating ophthalmic diseases such as glaucoma and ocular hypertension. The compound has a structure represented by formula (I), or is a stereoisomer, tautomer, solvate, metabolite, pharmaceutically acceptable salt, or prodrug of the structure represented by formula (I).

The invention relates to the technical field of biology, in particular to a polypeptide compound, a medicine for preventing and treating eye diseases and application. According to the present invention, a mitochondrial targeting module (triphenylphosphine) and a superoxide-initiated persulfide donor (SOPD) are integrated into a specific polypeptide to obtain the ROS-responsive mitochondrial targeting polypeptide compound; experiments show that the polypeptide compound has remarkable oxidative stress resistance, can effectively relieve RGC damage caused by intraocular hypertension, has a good prevention and treatment effect on glaucoma optic neuropathy, has the prevention and treatment effect obviously improved compared with that of other polypeptide compounds with similar structures, and has good biocompatibility and biological safety.

A method and device for reducing intraocular pressure in a patient. The method may comprise administering a viscoelastic material in Schlemm's canal to open aqueous humor outflow pathways. The device is adapted to perform the method. The viscoelastic material may be configured to lower the intraocular pressure within the eye.